Five Companies Dominate in Psychedelics-Based Drug Development

Healthcare >> Analyst Interviews >> October 31, 2024

Patrick R. Trucchio, CFA, is a Managing Director of Equity Research at H.C. Wainwright & Co. whose research focuses on biotechnology, specifically on immunology and inflammation, neurology, rare disease, and cardiology. Mr. Trucchio has 17 years of experience on the sell side. Prior to joining H.C. Wainwright, Mr. Trucchio was a senior equity research analyst at Berenberg Capital Markets (BCM) covering biotechnology and specialty pharmaceutical companies. Prior to Berenberg Capital Markets, Mr. Trucchio worked at Wells Fargo Securities and BMO Capital Markets. At Wells Fargo, Mr. Trucchio worked on an Institutional Investor ranked analyst team covering specialty pharmaceutical companies. Mr. Trucchio’s educational background includes an MBA with honors from St. John’s University and a B.S. in Finance with a minor in Economics from The Pennsylvania State University. Mr. Trucchio also has nine certificates from HMX Fundamentals/Pro, an online certificate program from Harvard Medical School. Profile

Word count: 4,568

TWST: Please introduce your firm, your role, and what you cover in terms of the psychedelics market.

Mr. Trucchio: I work at H.C. Wainwright,

Join for free to read a longer excerpt or purchase this article

Five Companies Dominate in Psychedelics-Based Drug Development

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Five Companies Dominate in Psychedelics-Based Drug Development

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS